Consumer healthcare group Futura Medical plc (AIM: FUM) reported on Monday positive results from an Early Feasibility Study of WSD4000, a topical treatment in development for female sexual dysfunction, demonstrating a highly statistically significant improvement in sexual function.

Study data from 12 women showed meaningful clinical benefit using the internationally recognised Female Sexual Function Index, with an average improvement of 6.35 units over baseline, exceeding the minimal clinically important difference of four units. Statistically significant gains were recorded across five of six domains, including arousal, lubrication, pain reduction, orgasm and satisfaction, with efficacy observed in both pre- and post-menopausal participants.

Additional assessment using the Female Sexual Encounter Profile across 56 encounters indicated consistent improvements in desire, arousal, lubrication and orgasm, with over 90% of uses resulting in conditions suitable for a satisfactory sexual experience. Genital sensation was reported in every use, typically within five minutes, while the product was well tolerated with no discontinuations.

Futura Medical said results support progression toward a Phase 3 programme, informed by a sham-controlled sensory study and a 200-subject home user study, both expected to report in mid 2026. The company highlighted the commercial significance given the absence of any regulatory-approved over-the-counter treatments for female sexual dysfunction, positioning WSD4000 as a potential first-in-class global opportunity.